ArticleACS omega2025
Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2 overexpression in breast cancer drives aggressive disease, treated clinically with monoclonal antibodies such as trastuzumab and pertuzumab. While effective, these therapies are limited by suboptimal pharmacokinetics and tumor penetration. Polyethylene glycol (PEG) conjugation can extend circulation half-life but may alter Fc-mediated interactions and receptor binding. Here, we used a multiscale computational framework to quantify PEGylation effects on the pertuzumab Fc domain. Structural models were generated with AlphaFold2, refined with RoseTTAFold2 to incorporate G0F-type glycans at Asn297, and site-specifically PEGylated via hydrazone linkages in UCSF ChimeraX. Aglycosylated control and PEGylated variants (1, 2, and 4 kDa) underwent 100 ns all-atom molecular dynamics simulations in GROMACS. Increasing PEG size produced stepwise RMSD elevations (1.1-13 nm) and hinge expansion (21.37-63.53 Å). RMSF analysis revealed domain-specific mobility shifts within the Fc region: CH2 flexibility in the control, CH3 mobility in the 1 and 2 kDa variants, and CH2/CH3 destabilization (>2.0 nm) in the 4 kDa system. Principal component analysis showed PC1 (45-70% variance) capturing hinge-closing and CH2 inward motion in controls, versus CH3 separation and CH2-CH3 displacement in PEGylated forms; the 4 kDa variant exhibited pronounced flexibility (PC2 ∼20 to 25%). Complementary backbone dihedral and hydrogen bond analyses showed localized torsional relaxation and a reduction in CH2-CH3 hydrogen bond occupancy in PEGylated systems, confirming the structural basis of hinge expansion. Vector projections indicated steric and entropic disruption of interdomain hydrogen bonds, suggesting reduced Fcγ receptor engagement. These results reveal PEG size-dependent structural perturbations, providing a molecular basis for diminished HER2 affinity and guiding rational design of PEGylated mAbs with optimized pharmacokinetics and preserved effector function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.